Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The chat will take place on January 18 at 1:30 PM ET. Investors can register for the live webcast through the provided link. Cardiff Oncology is focused on developing therapies leveraging PLK1 inhibition to treat various cancers, including KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. For more details, visit their official website.
Details
News Market Reaction – CRDF
The recorded move for CRDF in the trading session of this news was +1.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023.
Details of the fireside chat can be found below.
B. Riley Securities' 3rd Annual Oncology Conference | |
Date: | January 18, 2023 |
Time: | 1:30 PM ET |
Registration Link: | |
Those interested in viewing a live webcast of the fireside chat may register using the link above to gain access through the conference portal. A replay of the fireside chat will be available at the same location and archived for one year.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-b-riley-securities-3rd-annual-oncology-conference-301717462.html
SOURCE Cardiff Oncology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.